Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone emphasizes that the study finds no significant difference between 5 and 10 days of remdesivir treatment, with posts referencing clinical trials, adverse effects like nausea and kidney injury, and debates about the drug’s efficacy and safety. Words like 'no difference,' 'worse outcomes,' and 'dangerous' reflect cautious or critical attitudes, indicating moderate engagement with the study's implications.
The discussions show mixed opinions, with some skepticism about the drug's effectiveness and concerns about side effects, indicating neither strong agreement nor disagreement.
Few comments express deep curiosity; most are brief mentions or confirmations, suggesting moderate interest in the details of the study.
Posts reference specific studies, trial durations, and adverse effects, showing some level of thoughtful engagement but not deep analysis.
The discussions highlight that the study influences opinions on treatment duration and safety, but there is no indication of a broad, transformative change in perspectives.
Remdesivir o maior, sem efeito, é o SOLIDARITY da WHO ainda pre-print. https://t.co/OY3lTrxiQv https://t.co/tjlSk4suxp
@jackyAren85 @BrendaCrabtreeR @ferduende @CarlosdelRio7 @jsmadero @incmnszmx @InfectiousDz @_AGEI @APInfectologia @infectotuits @TAEscmid Mucho animo. Este documento detalla la escala ordinal de la #OMS: https://t.co/joZSREA1Jm La clasificación que uso combina la OMS con los estudios SIMPLE de #remdesivir en los que participamos: #COVID19 severo: https://t.co/KdR2zaDQnv y moderado: https://t.co/Tf3KC0AUSh
(NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encontrado diferencias significativas. https://t.co/wOYGa7dqdk
Remdesivir is not originally for COVID-19, but is an antiviral used for Ebola, MERS, SARS. Studies have shown that Remdesivir reduces time to recovery https://t.co/bUPiyGSrau
Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
No matter what aspect one looks at this drug is dangerous. https://t.co/cV2CzO5Nd3 https://t.co/fgxUiyrgx0
COVID-19 has caught up with President Donald Trump, highlighting the importance of safety measures. Vitamin D sufficiency, with levels at least 30 ng/mL, significantly reduces severe outcomes in COVID-19, suggesting…
Antivirals like interferon and remdesivir are key in COVID-19 management. Tocilizumab may help recover non-responders. The Theodore Roosevelt aircraft carrier showed most infected sailors remain asymptomatic with low…
@mpc_xetts @PNWShan @rosegarden826 @mlfrostmi @MdBreathe I don't know. But I did find this. You can probably assess better than I. https://t.co/UoO8MXprXf
@Sober_Atheist @DrNeilStone Kennedy included peer-reviewed studies such as https://t.co/beKi6405y9. However, like practically every other institution these days, leading medical journals like JAMA and Lancet have been corrupted and are often bought and paid for. https://t.co/2z74wL5Ovz
@JordanA8156 @RandPaul According to the New England Journal of Medicine The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%) https://t.co/daqxmv8i4j
@DopplerEffect93 @SabinehazanMD @DrJackieStone It is! UN debatable Ventilator s were used irresponsibly. Brutal drug. https://t.co/l8JUvY7qct
@alanlremick @Grandma04242012 @mtioran @VigilantFox Lol. Even Gilead the company who makes Remdesevir, had to admit that the linger you were on it the greater the chance that it would kill you. https://t.co/FJdj6xrjB5
@jvgraz I gave you a recent study. I can give you an even older study from when Remdesivir was first approved https://t.co/ea4lyKdhcN Notice he can’t despite on Remdesivir’s efficacy or that Remdesivir and mechanics ventilation don’t occur together. Stay in software development
@Terence_009 @ztkelly @DrAseemMalhotra Treatment is 3-5d in most cases as we have evidence that extending the treatment to 10d does not improve clinical outcomes in Covid-19 (which is how evidence based medicine works) https://t.co/xJa1K5W7ui
@MdBreathe Fauci & Remdesivir
How long does remdesivir treatment take? Remdesivir for 5 or 10 Days in #patients with #severe #COVID19. Visit: https://t.co/KMNzM64Hem Submit Research Work at: https://t.co/V61MBAMpHD https://t.co/VsItYv5hoF
RT @EinsteinPhilaID: A little light reading on each topic... https://t.co/yXqJOSvMXC https://t.co/fGOeEzlaPP https://t.co/41e3QOUjIb https:…
A little light reading on each topic... https://t.co/yXqJOSvMXC https://t.co/fGOeEzlaPP https://t.co/41e3QOUjIb https://t.co/pJI59cUQtR https://t.co/AjnUhBRl8T https://t.co/W0CV7Lhjv0
@ScottAdamsSays A study of patients treated with Remdesivir for either five or 10 days. A four-fold higher rate of acute kidney injury occurred with the longer treatment, an outcome not readily discerned when major and minor adverse events are reported in aggregate. https://t.co/hJSvwwe2ar
Gilead sponsored the SIMPLE trials to assess the efficacy of IV RDV in severe and mild/moderate COVID patients comparing 5- vs. 10-day RDV. No placebo CT in either of these trials and they explicitly say that the magnitude of benefit is uncertain. 5/10 https://t.co/bxWwvOgI6A
No matter what aspect one looks at this drug is dangerous. https://t.co/cV2CzO5Nd3 https://t.co/fgxUiyrgx0
5 days of death or 10 days of death study. Funny how no footnotes on remdesivir being a "potent anti-viral" https://t.co/cV2CzO5Nd3 https://t.co/QfgHPmmtvz
@kcrnicu523 @USMC_Buckeye https://t.co/AbWbawbaZQ https://t.co/Fcaj9bf7gm
@Amerita @becausejoanna @TheEyesAlready @newjuels @thevivafrei https://t.co/AiWx83XYeL
#002 Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 DOI: 10.1056/NEJMoa2015301
11-12-2020: Ippolito and Cortegiani of Palermo, Italy discuss Jason Goldman's remdesivir study and Christoph Spinner's remdesivir study https://t.co/fmoCGINNPG https://t.co/4ns0wtqFqn https://t.co/YtrFRh2FbH https://t.co/Yaf1k1k9Ta https://t.co/lBvsxVutwZ https://t.co/c4FgwzW6dV
Remdesivir is not originally for COVID-19, but is an antiviral used for Ebola, MERS, SARS. Studies have shown that Remdesivir reduces time to recovery https://t.co/bUPiyGSrau
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/cS6GgaAVNO
@AmroodAdmi And this study shows how it doesn't work in severe cases Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/p9K7HPxBqr
RT @FranciscoMarty_: @jackyAren85 @BrendaCrabtreeR @ferduende @CarlosdelRio7 @jsmadero @incmnszmx @InfectiousDz @_AGEI @APInfectologia @inf…
@jackyAren85 @BrendaCrabtreeR @ferduende @CarlosdelRio7 @jsmadero @incmnszmx @InfectiousDz @_AGEI @APInfectologia @infectotuits @TAEscmid Mucho animo. Este documento detalla la escala ordinal de la #OMS: https://t.co/joZSREA1Jm La clasificación que uso combina la OMS con los estudios SIMPLE de #remdesivir en los que participamos: #COVID19 severo: https://t.co/KdR2zaDQnv y moderado: https://t.co/Tf3KC0AUSh
https://t.co/OEeLQwSyLC
RT @giovannilandoni: #Remdesivir reduced hospital stay in #COVID19 (but 10 days of #Remdesivir treatment worse than 5 days: mortality 11% v…
RT @giovannilandoni: #Remdesivir reduced hospital stay in #COVID19 (but 10 days of #Remdesivir treatment worse than 5 days: mortality 11% v…
@MaLoSolV Le daría muchas razones, pero solo le voy a citar ✌
@SuplafiPla8 @HLGatell @COFEPRIS Aquellos que basan sus argumentos mentales en revistas como el TvNotas, TVyNovelas o el Hola, allá ellos, déjelas a un lado por un instante y piense, hay otras lecturas que le pueden ser de utilidad. #QuedateEnCasa Le invito a leer la evidencia científica: https://t.co/HHE9FX7BfH
RT @giovannilandoni: #Remdesivir reduced hospital stay in #COVID19 (but 10 days of #Remdesivir treatment worse than 5 days: mortality 11% v…
#Remdesivir reduced hospital stay in #COVID19 (but 10 days of #Remdesivir treatment worse than 5 days: mortality 11% vs 8%) 6/ https://t.co/VexlUz0V4F
@Marylu58121349 @FraLauricella @matteosalvinimi In verità sì, ci sono degli studi sul Remdesivir che ne hanno dimostrato l'efficacia https://t.co/D3zLGazYVU
https://t.co/rHPbaJOo06
Article from this weeks NEJM about Remdesivir. Interesting that they didn't have a placebo group, but I guess you work with what you can get. https://t.co/hzm1n9wa5k #covid #corona #covid19 #medicine #NEJM #remdesivir
8/10 What about the duration of remdesivir? Two open-label (non placebo-controlled studies) show that 5 days is likely equal to 10 days of remdesivir in patients with moderate https://t.co/x6CPspKA6B or severe #COVID19 on 7 point clinical ordinal scale https://t.co/ZCrFcs6a00 https://t.co/3GuVUdFsUa
#NEJM Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/49dqkndemQ In patients with severe Covid-19 not requiring mechanical ventilation, the trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir.
RT @otavio_ranzani: Remdesivir o maior, sem efeito, é o SOLIDARITY da WHO ainda pre-print. https://t.co/OY3lTrxiQv https://t.co/tjlSk4suxp
Remdesivir o maior, sem efeito, é o SOLIDARITY da WHO ainda pre-print. https://t.co/OY3lTrxiQv https://t.co/tjlSk4suxp
RT @BITNavarra: (NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encont…
RT @BITNavarra: (NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encont…
RT @BITNavarra: (NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encont…
RT @BITNavarra: (NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encont…
RT @BITNavarra: (NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encont…
10 days remdesivir is no better than 5 days. https://t.co/tAgn8tnbZR
RT @BITNavarra: (NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encont…
(NEJM) Remdesivir durante 5 ó 10 días en pacientes con formas graves de COVID-19 sin ventilación mecánica: no se han encontrado diferencias significativas. https://t.co/wOYGa7dqdk
https://t.co/ERS1QamJf1
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/cEUVu8rKUU https://t.co/QfPiyZwpkm
In any case 5 days of #remdesivir for #COVID19 seem enough... https://t.co/aDJ4eHpPzK
No habría diferencia entre un curso de 5d y uno de 10d de remdesivir en pacientes con COVID severo que no requieren ventilación mecánica https://t.co/Sih7qEHgvX
This article explores how #remdesivir reacts for 5 or 10 days in patients with #COVID19. @NEJM #ScienceTwitter DOI: 10.1056/NEJMoa2015301
Print del preprint... Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/ZU7BK9vEgP
レムデシビル、効果に有意差がみられなかったらしい。副作用もやっぱり多いな…。https://t.co/oNszqwWGca
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/z254ccnz7T
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/BTBIExdVjR
@PreetiSangwan17 "In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir." Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Goldman JD et al. NEJM 27 May 2020
RT @victoriacyanide: @NIAIDNews ACTT-1 trial with #Remdesivir in severe #COVID19 cases gave RDV for 10 days. Food for thought: would 5 day…
RT @victoriacyanide: @NIAIDNews ACTT-1 trial with #Remdesivir in severe #COVID19 cases gave RDV for 10 days. Food for thought: would 5 day…
The RTC for Remdisivir found that the only benefit to patients came with a 10 day course. So I'd super like to know how Trump was "done" with therapeutics by Thursday. https://t.co/prpto229BA
RT @victoriacyanide: @NIAIDNews ACTT-1 trial with #Remdesivir in severe #COVID19 cases gave RDV for 10 days. Food for thought: would 5 day…
@NIAIDNews ACTT-1 trial with #Remdesivir in severe #COVID19 cases gave RDV for 10 days. Food for thought: would 5 day RDV treatment have shown similar efficacy? Below: 5 v 10 day RDV in severe cases (no CT) apparently no sig. difference @FranciscoMarty_ https://t.co/a6l2J5NUqy https://t.co/HN6We7ltv3 https://t.co/QypvPA7GWj
RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
.@nephjc RT @edgarvlermamd: Remdesivir for #COVID19 #AskRenal https://t.co/y9QEvToMRL https://t.co/aXi7KGzNHW
Remdesivir for #COVID19 #AskRenal https://t.co/TpO2FTYnpy https://t.co/cY4InmuZ2x
So did POTUS get his first dose Friday? Five day treatment would keep him at Walter Reed until Tuesday. @MollyJongFast @jaketapper @JRubinBlogger #TrumpHasCovid https://t.co/34qBur5015
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/Dgdx0q7eJ8
@rsg Agree broadly with the sentiment. Remdesivir is also either a 5 or 10 day experimental treatment, so he'll lively be at Walter Reed for some time. https://t.co/6DSlBuNK7o.
According to SIMPLE study, the first injection dose of 5-day treatment course would be 200mg, plus 100mg q.d. for following 4 days. https://t.co/oojpibVN8x https://t.co/VVgpOYyz6C
May 27, 2020 DOI: 10.1056/NEJMoa2015301 Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/0et1Q6QXPo
7/ Prior trials 2/2 ii) in sick but not critical, Remy 5d idential to 10d - https://t.co/nqeeUNxnGr - sick non-critical (hospitalized, need O2, not on vent) :) ~ 50% had 2pt improvement on scale :( open-label, no placebo ctrl. didn't learn much, 5 just as good (useless?) as 10d
@CovidAnalysis Look at this Remdesivir trial by $GILD. 27% of the patients also received HCQ, & had lower mortality than the non-HCQ group (9% vs 12%, not statistically significant). But the HCQ group might have been initially sicker than the non-HCQ one. https://t.co/Tjwc2jXVq7
#UnionStrong #COVID19 Suh was named as a KP SoCal contributor on page four of the appendix: https://t.co/cQ0MSMoMiC
RT @InfMicPrevHUVR: EC aleatorizado en px hipoxémicos con neumonía #COVIDー19 SIN ventilación mecánica invasiva: ✴️ 5 días vs 10 de tto IV…
@DIVIZIO1 @NIH Oui et il y a d’autres. SIMPLE 400 patients sous remdé. On peut pas juger efficacité car tous sous remdesivir mais on peut juger safety. Vraiment irritant ces gens qui ne lisent pas la littérature scientifique et divaguent ! https://t.co/prTgouqZT8 https://t.co/l9N4LOml9c
#8 A concurrent study investigated 5- versus 10-day remdesivir in patients with severe Covid-19 indicated similar outcomes in both treatment arms. https://t.co/1ZPy9derCx
10/19:
RT @ACCinTouch: A panel of experts is reviewing some of the key #COVID19 research during our #ACCEd Summer Session right now. View this NEJ…
RT @ACCinTouch: A panel of experts is reviewing some of the key #COVID19 research during our #ACCEd Summer Session right now. View this NEJ…
A panel of experts is reviewing some of the key #COVID19 research during our #ACCEd Summer Session right now. View this NEJM paper on #remdesivir here: https://t.co/GwPlT2yQSW.
TIR: Remdesivir for 5 or 10 days Answering the question - In patients with COVID-19 pneumonia is a 5 day course as effective as a 10 day course of remdesivir in improving clinical course at 14 days? https://t.co/bMU38aGGoa
RT @StefaniaArciell: Remdesivir for 5 or 10 Days in Patients With Severe COVID-19 - American College of Cardiology https://t.co/MPiaqBoFmS
Remdesivir for 5 or 10 Days in Patients With Severe COVID-19 - American College of Cardiology https://t.co/MPiaqBoFmS
There is also another study that compared 5 vs 10 days of treatment. This doesn't provide any evidence about whether remdesivir is an effective treatment, as there wasn't a placebo arm https://t.co/ARGZ3btVZz
Aktuelle Erkenntnisse zum Hoffnungsträger #Remdesivir (RDV) im Kampf gegen die #Corona-Pandemie: RDV auch nach kurzer Behandlungsdauer wirksam: https://t.co/NA4G9eB4w5 #healthcarePR #medictum https://t.co/ZLKqd6nevm
#Remdesivir durante 5 o 10 días en pacientes con #covid-19grave ¿Cuánto tiempo deben tratarse las personas con COVID-19 grave con Remdesivir? @JWatch @NEJM https://t.co/HZqjht1kLm https://t.co/rd9WNM6be6 https://t.co/uEdNea0rDK
A new study was published in the New England Journal of Medicine called "Remdesivir for 5 or 10 Days in Patients with Severe Covid-19." You can request this article through your library resources. https://t.co/TxkRHiZ18V
Great infographic here re: remdesivir 5 vs 10 days. https://t.co/wMyTWzxhis https://t.co/7Lv6gUbZXo
@BThekick @Babar_85_ @dupontaignan Tiens ça te fera de la lecture même si j'ai de forts doutes sur ta capacité intellectuelle à comprendre quoi que ce soit. https://t.co/sQEA4wFJiA Bisous mon Troll chéri
RT @ialwaili: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/wajMFjmW56
RT @MonsieurQFB: El nuevo estudio sobre Remdesivir se concluyó que usarlo por 5 y 10 días no tiene diferencia significativa y que por no te…
RT @JeanYvesTarrade: Qui m'explique ? Etude @NEJM sur la durée d'efficacité du #remdesivir. 5j = 0 décès 10j = 12 décès Ah si @raoult_…
RT @JeanYvesTarrade: Qui m'explique ? Etude @NEJM sur la durée d'efficacité du #remdesivir. 5j = 0 décès 10j = 12 décès Ah si @raoult_…
RT @JeanYvesTarrade: Qui m'explique ? Etude @NEJM sur la durée d'efficacité du #remdesivir. 5j = 0 décès 10j = 12 décès Ah si @raoult_…
RT @JeanYvesTarrade: Qui m'explique ? Etude @NEJM sur la durée d'efficacité du #remdesivir. 5j = 0 décès 10j = 12 décès Ah si @raoult_…
RT @JeanYvesTarrade: Qui m'explique ? Etude @NEJM sur la durée d'efficacité du #remdesivir. 5j = 0 décès 10j = 12 décès Ah si @raoult_…
RT @aragon_jb: @JeanYvesTarrade @NEJM @raoult_didier Oui, c'est comique... mais en fait, les patients meurent aussi dans le gr. 5 jours "N…
RT @JeanYvesTarrade: Qui m'explique ? Etude @NEJM sur la durée d'efficacité du #remdesivir. 5j = 0 décès 10j = 12 décès Ah si @raoult_…
RT @aragon_jb: @JeanYvesTarrade @NEJM @raoult_didier Oui, c'est comique... mais en fait, les patients meurent aussi dans le gr. 5 jours "N…
Flawed trial means it remains unclear how 10-day and 5-day #Remdesivir treatment compare: https://t.co/gnEe83BOY5 #coronavirus #covid19
Remdesivir for 5 or 10 Days in Patients With Severe Covid-19 https://t.co/yruNp7clbv
RT @DoctorDrug_: Remdesivir for 5 or 10 Days in Patients with Severe #COVID19 Covid-19 https://t.co/CbpFw20fIF https://t.co/2T62aj5vMM
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/Qz6xRgVge9
Remdesivir es eficaz contra Covid-19 incluso después de cortos períodos de tratamiento. https://t.co/IfRmZ3XX8D
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/wyn51uKETp
Clinical trial from @NCBI: Patients with severe cases of #COVID19 and the results of #remdesivir for 5 to 10 days. https://t.co/OuwdhmaFV6 Found on https://t.co/jlpglX8egw Powered by MM
Remdesivir for 5 or 10 Days in Patients With Severe COVID-19 - American College of Cardiology https://t.co/NRfQIdXPKp
RT @carpe_diem0820: 人口呼吸器を必要としないCOVID-19患者では、レムデシビル5日間による治療は10日間と、14日目での臨床的改善に有意差なし 供給が限定的なら、初期の病態にある患者に対し、5日間の治療を優先すべき Remdesivir for 5 o…
RT @mariodelg: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. https://t.co/vaCQ9yFWNu
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. https://t.co/vaCQ9yFWNu
重症COVID19患者に対するremdesivir投与期間は5日と10日で症状改善に差はなかった。 Remdesivir for 5 or 10 Days in Patients With Severe Covid-19 https://t.co/lB4IpOs7YI
RT @COVID19Evidence: #COVID #COVID19 #coronavirus #corona #Covid19remdesivir #EBM Remdesivir for 5 or 10 Days in Patients with Severe Covid…
#COVID #COVID19 #coronavirus #corona #Covid19remdesivir #EBM Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. https://t.co/2OaHuFOvVR
RT @Globalbiosec: Remdesivir for 5 or 10 Days in Patients with Severe #Covid19 | NEJM https://t.co/Q4Op24HWBs
RT @Globalbiosec: Remdesivir for 5 or 10 Days in Patients with Severe #Covid19 | NEJM https://t.co/Q4Op24HWBs
RT @AhernStephane: #covid19 Un autre échec de traitement ... il faudra poursuivre le travail EvidenceAlerts | Remdesivir for 5 or 10 D…
#covid19 Un autre échec de traitement ... il faudra poursuivre le travail EvidenceAlerts | Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. https://t.co/pNQpvt7c71
Trending on PubMed: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. https://t.co/HMTkjIVOxX
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/ncKCdD2g2i
(SIETES) Remdesivir for 5 or 10 days in patients with severe covid-19 https://t.co/D8mCNS66Jb
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/X6h1BMwsEf
#Remdesivir for 5 or 10 Days in Patients with Severe #Covid19 | NEJM https://t.co/SKdYYbJbCa
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/VA5j2IXiJs
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/tRmUYV3A4g
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM – https://t.co/WV1KXSxHqR https://t.co/KBvexQMGsw
RT @aussiecoley: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/omQn38qprB
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/omQn38qprB
RT @ymori117: NEJM: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/IqvXR6RuLg こちらの主要評価項目は7ポイントのスケール。5日間の点滴で済みそうな…
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/AdWIcWSrfL
RT @DraSoniaLopez: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/Vbhiah3d6y
Remdesivir for 5 or 10 Days in Patients with Severe #Covid19 | NEJM https://t.co/Q4Op24HWBs
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/5QN9d0Lv05
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/LHn6pFb4In
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/wajMFjmW56
RT @ymori117: NEJM: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/IqvXR6RuLg こちらの主要評価項目は7ポイントのスケール。5日間の点滴で済みそうな…
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/GcCJQgPsRX
NEJM: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/IqvXR6RuLg こちらの主要評価項目は7ポイントのスケール。5日間の点滴で済みそうなのはありがたい。
RT @DraSoniaLopez: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/Vbhiah3d6y
Remdesivir for 5 or 10 Days in Patients with Severe #COVID19 Covid-19 https://t.co/CbpFw20fIF https://t.co/2T62aj5vMM
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/UJoNvb7FKg
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/Vbhiah3d6y
＃未読 ③本 https://t.co/c10TyKhuzF https://t.co/Io1IYU2maM https://t.co/4cWnIkiVgQ
New @NEJM article just mentioned: "Remdesivir for 5 or 10 Days in Patients with Severe Covid-19" https://t.co/EPFBTfC0o0 #CADTHTalks
Remdesivir for 5 or 10 days in patients with severe COVID-19 https://t.co/O79kjDHns6
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
RT @miakiza20100906: 論文（無料・査読後）： Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/daVKnlTTHa 2020年、Goldman（スイス医療セ…
RT @miakiza20100906: 論文（無料・査読後）： Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/daVKnlTTHa 2020年、Goldman（スイス医療セ…
RT @miakiza20100906: 論文（無料・査読後）： Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/daVKnlTTHa 2020年、Goldman（スイス医療セ…
RT @miakiza20100906: 論文（無料・査読後）： Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/daVKnlTTHa 2020年、Goldman（スイス医療セ…
RT @miakiza20100906: 論文（無料・査読後）： Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/daVKnlTTHa 2020年、Goldman（スイス医療セ…
論文（無料・査読後）： Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 https://t.co/daVKnlTTHa 2020年、Goldman（スイス医療センター）ら。レムデシビルの臨床試験結果。対象者は人工呼吸器が必要でない12歳以上の新型コロナ患者397人。
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
RT @ABsteward: Just Published @NEJM RCT : Remdesivir for 5 or 10 Days in Patients with Severe #COVID19 #IDTwitter https://t.co/FIt7eqLA1N…
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. https://t.co/QB0YQEdCQH
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM @JRBneuropsiq @carlos_sierra @germanfajardo @jsmadero https://t.co/QVsw4nT28u
#Remdesivir for 5 or 10 Days in Patients with Severe #Covid19 @NEJM @GileadSciences @CDCgov @HealthyFla @WHO https://t.co/4INXWWStGd
RT @DrChoueiri: Just now: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 @NEJM —5 days may be enough —shorter duration is o…
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/Tcj1NmsLNw
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
RT @Transplant_Doc: Remdesivir for 5 or 10 Days in Patients with Severe #Covid_19. In severe Covid-19 patients not requiring mechanical ven…
RT @ABsteward: Just Published @NEJM RCT : Remdesivir for 5 or 10 Days in Patients with Severe #COVID19 #IDTwitter https://t.co/FIt7eqLA1N…
Remdesivir for 5 or 10 Days in Patients with Severe #Covid_19. In severe Covid-19 patients not requiring mechanical ventilation, this trial did not show a significant difference between a 5-day or a 10-day course of #remdesivir. #coronavirus @NEJM https://t.co/hwXD15QmCf
Trend up+1: *Goldman JD* et al (N Engl J Med) __Remdesivir for 5 or 10 Days in Patients with Severe Covid-19__ https://t.co/304FqzE0h9
RT @CarlosdelRio7: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/v3frA4x6EH "In patients with severe #CO…
RT @CarlosdelRio7: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/v3frA4x6EH "In patients with severe #CO…
#Remdesivir for 5 or 10 Days in Patients with Severe #COVID19 | NEJM #ResearchMatters #LetScienceEducateLawmakers and Everyone else! https://t.co/gHaNJDOZNW
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/ofhglAmwYl
RT @carpe_diem0820: 人口呼吸器を必要としないCOVID-19患者では、レムデシビル5日間による治療は10日間と、14日目での臨床的改善に有意差なし 供給が限定的なら、初期の病態にある患者に対し、5日間の治療を優先すべき Remdesivir for 5 o…
RT @ABsteward: Just Published @NEJM RCT : Remdesivir for 5 or 10 Days in Patients with Severe #COVID19 #IDTwitter https://t.co/FIt7eqLA1N…
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
RT @influenzer3: これでもRCTとして成立していると言えるのかは謎。 結果を見ると、人工呼吸器以上の重症例では10日投与を検討しても良いような気がします。 Remdesivir for 5 or 10 Days in Patients with Severe C…
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/MsVTiFhlZz
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/R8XE75a8AU
Nice work @Swedish and @Providence and Jason Goldman, George Diaz and others: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM https://t.co/2rMdEaaZ7L
The New England Journal of Medicine. https://www.nejm. org/doi/full/10.1056/NEJMoa2015301. Published May 27, 2020. Accessed October 24, ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 share. Neuroscience ...
... 10.1056/NEJMoa2015301). June 2, 2020, Research Update. Remdesivir Shortens Recovery Time in Hospitalized Patients with COVID-19 and Lower Respiratory Tract ...
... doi: 10.1056/NEJMoa2015301. Last updated 12 February 2021 18:52. Citation: The Pharmaceutical Journal, PJ, June 2020, Vol 304, No 7938;304(7938):DOI: ...
https://doi.org/10.1056/NEJMoa2015301. 3. Baang, J. H. et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an.
doi:10.1056/NEJMoa2015301. [11] Gillenwater, Samantha et al. “Remdesivir for the Treatment of Covid-19 - Preliminary Report.” The New England ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
doi:10.1056/NEJMoa2015301. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020; 383: 1827-1837. doi: 10.1056/NEJMoa2015301. 7. Ayed M, Borahmah ...
doi: 10.1056/NEJMoa2015301 [PubMed]; 32470486 Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
doi: 10.1056/NEJMoa2015301 [PubMed]; 32470486 Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID ...
doi:10.1056/NEJMoa2015301; Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with ...
94.Goldman et al., NEJM, doi: 10.1056/NEJMoa2015301, Remdesivir for 5 or 10 Days in Patients with Severe Covid-19, https://www ...
doi: 10.1056/NEJMoa2015301. Accelerated Access Review. 2016. Available at: https://www.gov.uk/government/publications/independent-review ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
2020;doi:10.1056/NEJMoa2015301. Kahn MS, et al. J Am Heart Assoc. 2020;doi:10.1161/JAHA.119.015594. Click here to read the Cover Story ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
doi: 10.1056/NEJMoa2015301. pmid:32459919. 39. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of ...
2020;NEJMoa2015301. doi:10.1056/NEJMoa2015301; Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
... page four of the appendix: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2015301/suppl_file/nejmoa2015301_appendix.pdf".
... 10.1056/NEJMoa2012410 · https://www.nejm.org/doi/full/10.1056 ... NEJMoa2015301 · https://www.nejm.org/doi/full/10.1056/NEJMoa1916624 · https ...
Remdesivir for 5 or 10 days in patients with severe Covid-19 [published online May 27, 2020]. N Engl J Med. doi: 10.1056/NEJMoa2015301. Pages: 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
2020;10.1056/NEJMoa2015301. [PubMed] [PDF]; Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
DOI: 10.1056/NEJMoa2015301. 2. Beigel J, Tomashek K, et al. Remdesivir for the Treatment of Covid-19-Preliminary Report. New England Journal ...
DOI: 10.1056/NEJMoa2015301. Picks for you. The COVID-19 coronavirus epidemic has a natural origin, study · Coronavirus could infect embryos as ...
2020;doi:10.1056/NEJMoa2015301. Published by: infectious disease news logo. Sources/Disclosures. Source: Healio Interviews. Disclosures: Creech ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2015301. Currently rated 4.8 by 4 people. Posted in: Drug Trial News | Medical Research News ...
... 10.1056/NEJMoa2015301) publizierten Ergebnisse zeigen. Das empfohlene Schema für Remdesivir, das derzeit im Rahmen von Heilversuchen ...
doi:10.1056/nejmoa2015301. 2. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
org/doi/full/10.1056/NEJMoa2015301. Episode 12: COVID-19 and Infectious Diseases. Ttocs Ccolst and 4 others. 5 reactions ·. 1 comment. ·. 1 ...
OR
FM
BN
R
EL
LS
PF
WW
SD
B
IM
S
CS
K
BB
R
EF
KB
VY
OK
LF
鯵C
RC
D
TD
A
IC
MC
ST
VP
AC
GM
M
RA
JY
KB
FV
TP
D
CS
CV
JA
FT
MP
C
F
KM
GZ
I
OI
CD
ジニ
MH
JM
SK
I
IS
GM
SN
JF
FI
AC
A
C
VM
AC
BW
MB
MC
OL
UU
DM
NS
IR
TP
ᵏᵒ
JB
AC
KN
MT
SA
AC
M
DG
L
EM
EL
لا
CU
TC
M
N
B
DD
G
IM
AG
Sद
M
Z
M
EE
M
イ
E
CA
O
E
AD
SA
PT
JI
S
ʜ
GA
AP
CC
SN
TG
NC
青
JM
S
RM
イ
DB
اا
U
AM
森
ME
EM
D
RS
DL
青
CA
こゆ
白即
あ
KT
たF
と
MP
KS
PL
GM
MG
P
CD
彫
AA
か
CC
AG
MQ
TL
DH
GR
YG
大
お
EC
さT
T
バ
GS
CM